A microfluidics-based mobility shift assay to discover new tyrosine phosphatase inhibitors

Journal of Biomolecular Screening

Volumn 11, Issue 8, 2006, Pages 996-1004

  Perrin, Dominique ^a   Frémaux, Christèle ^a   Besson, Dominique ^a   Sauer, Wolfgang H B ^a   Scheer, Alexander ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

DiFMUP; Mobility shift assay; Nanofluidics; Peptide substrate; Protein tyrosine phosphatase

Indexed keywords

6,8 DIFLUORO 4 METHYLUMBELLIFERYLPHOSPHATE; DIFMUP; ENZYME INHIBITOR; PHOSPHOPEPTIDE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR;

ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; INTERMETHOD COMPARISON; MICROFLUIDIC ANALYSIS; MOBILITY SHIFT ASSAY; NONHUMAN; OBESITY; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

DRUG EVALUATION, PRECLINICAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; MICROFLUIDICS; PEPTIDYL TRANSFERASES; PROTEIN-TYROSINE-PHOSPHATASE; STRUCTURE-ACTIVITY RELATIONSHIP; VANADATES;

EID: 33751565987     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057106294094     Document Type: Article

References (23)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsasam S: The protein kinase complement of the human genome. Science 2002;298:1912-1934.
2. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, et al: Protein tyrosine phosphatases in the human genome. Cell 2004;117:699-111.
3. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, et al: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999;283:1544-1548.
4. Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 2000;20:5479-5489.
5. Hooft van Huijsduijnen R, Sauer WHB, Bombrun A, Swinnen D: Prospects for inhibitors of protein tyrosine phosphatases as antidiabetic drugs. J Med Chem 2004;47:4142-4146.
6. Espanel X, Wälchli S, Pescini Gobert R, El Alama M, Curchod ML, Gullu-Isler N, et al: Pulling strings below the surface: hormone receptor signaling through inhibition of protein tyrosine phosphatases. Endocrine 2001;15:19-28.
7. Hooft van Huijsduijnen R, Wälchli S, Ibberson M, Harrenga A: Protein tyrosine phosphatases as drug targets; PTP1B and beyond. Expert Opin Ther Targets 2002;6:637-647.
8. Hooft van Huijsduijnen R, Bombrun A, Swinnen D: Selecting protein tyrosine phosphatases as drug targets. Drug Discov Today 2002;7:1013-1019.
9. Gee KR, Sun WC, Bhalgat MK, Upson RH, Klaubert DH, Latham KA, et al: Fluorogenic substrates based on fluorinated umbelliferones for continuous assays of phosphatases and beta-galactosidases. Anal Biochem 1999;273:41-48.
10. Welte S, Baringhaus KH, Schmider W, Müller G, Petry S, Tennagels N: 6,8-Difluoro-4-methylumbiliferyl phosphate: a fluorogenic substrate for protein tyrosine phosphatases. Anal Biochem 2005;338:32-38.
11. Lanzetta PA, Alvarez LJ, Reinach PS, Candia OA: An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem 1979;100:95-97.
12. Nishikata M, Suzuki K, Yoshimura Y, Deyama Y, Matsumoto A: A phosphotyrosine-containing quenched fluorogenic peptide as a novel substrate for protein tyrosine phosphatases. Biochem J 1999;343:385-391.
13. Perrin D, Frémaux C, Scheer A: Assay development and screening of a serine/threonine kinase in an on-chip mode using caliper nanofluidics technology. J Biomol Screen 2006;11:359-368.
14. Kerby M, Chien RL: A fluorogenic assay using pressure-driven flow on a microchip. Electrophoresis 2001;22:3916-3923.
15. Malamas MS, Sredy J, Moxham C, Katz A, Xu W, McDevitt R, et al: Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J Med Chem 2000;43:1293-1310.
16. Zhang J-H, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
17. Ryan AJ, Gray NM, Lowe PN, Chung CW: Effect of detergent on "promiscuous" inhibitors. J Med Chem 2003;46:3448-3451.
18. Espanel X, Sudol M: Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem 2001;276:14514-14523.
19. Espanel X, Huguenin-Reggiani M, Hooft van Huijsduijnen R: The SPOT technique as a tool for studying protein tyrosine phosphatase substrate specificities. Protein Sci 2002;11:2326-2334.
20. Gaudet EA, Huang KS, Zhang Y, Huang W, Mark D, Sportsman JR: A homogeneous fluorescence polarization assay adaptable for a range of serine/threonine and tyrosine kinases. J Biomol Screen 2003;8:164-175.
21. Perrin D, Martin T, Cambet Y, Frémaux C, Scheer A: Overcoming the hurdle of fluorescent compounds in kinase screening: a case study. Assay Drug Dev Technol 2006;4:185-196.
22. Sills MA, Weiss D, Pham Q, Schweitzer R, Wu X, Wu JJ: Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening. J Biomol Screen 2002;7:191-214.
23. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 2001;46:3-26.